• South Korea’s MFDS granted marketing authorization for Hanmi Pharmaceutical’s Efpeo Auto-Injector (efpeglenatide), an obesity drug for chronic weight management.
• Approval covers five strengths; indicated for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity.
• Authorization date Oct. 7, 2026; Hanmi targets domestic launch by year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007800667), on October 07, 2026, and is solely responsible for the information contained therein.